secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001193125-23-290972
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences prices $100M public offering of 20M shares at $5.00; pipeline updates also disclosed
--------------------------------------------------------------------------------

- Underwritten public offering of 20M ordinary shares at $5.00/share, gross proceeds ~$100M; 30-day option for additional 3M shares.
- Offering expected to close Dec 11, 2023; J.P. Morgan and Leerink Partners are joint book-runners.
- Cash runway (including offering net proceeds and $20M GSK milestone) expected to fund operations into Q4 2025.
- Initiated dosing in RestorAATion trial for WVE-006 (AATD); earned $20M GSK milestone; proof-of-mechanism data expected 2024.
- INHBE clinical candidate for metabolic disorders including obesity expected Q4 2024 selection, CTA in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523290972/0001193125-23-290972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523290972/d60594d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-290972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer